(Q41674321)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26070269%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

title

ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26070269%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26070269%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

author name string

Jin Wang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26070269%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Chao Zhang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26070269%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Keming Chen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26070269%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Hailin Tang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26070269%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Jun Tang

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26070269%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Cailu Song

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26070269%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

language of work or name

English

0 references

publication date

13 June 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26070269%20AND%20SRC:MED&resulttype=core&format=json

Breast Cancer Research and Treatment

17 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26070269%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

volume

152

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26070269%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26070269%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

page(s)

255-269

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26070269%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10549-015-3467-3

17 February 2020

exact match

0 references

cites work

Triple-Negative Breast Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Gene-expression signatures in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Estrogen receptor beta in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Cloning of a novel receptor expressed in rat prostate and ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Estrogen receptors and proliferation markers in primary and recurrent breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

The different roles of ER subtypes in cancer biology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Expression of both estrogen receptor-beta 1 (ER-β1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-α)-negative early breast cancer (EB

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Differential expression of estrogen receptor α, β1, and β2 in lobular and ductal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

AKT regulation of estrogen receptor beta transcriptional activity in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

The potential role of estrogen receptor β2 in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Oestrogen receptor beta and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Wnt signaling in triple negative breast cancer is associated with metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Comprehensive molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

REporting recommendations for tumor MARKer prognostic studies (REMARK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Targeting Akt3 signaling in triple-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

ERbeta exerts multiple stimulative effects on human breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

The basics of epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Regulation of IMP3 by EGFR signaling and repression by ERβ: implications for triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Research resource: global identification of estrogen receptor β target genes in triple negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Co-expression of EGFR and CK5/6 in primary squamous cell carcinoma of the breast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Locoregional and distant recurrences after breast conserving therapy in patients with triple-negative breast cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3

Immunohistochemical detection of phospho-Akt, phospho-BAD, HER2 and oestrogen receptors alpha and beta in Malaysian breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3467-3